Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 26;70(47):1635-1639.
doi: 10.15585/mmwr.mm7047a3.

Racial, Ethnic, and Gender Disparities in Awareness of Preexposure Prophylaxis Among HIV-Negative Heterosexually Active Adults at Increased Risk for HIV Infection - 23 Urban Areas, United States, 2019

Collaborators, Affiliations

Racial, Ethnic, and Gender Disparities in Awareness of Preexposure Prophylaxis Among HIV-Negative Heterosexually Active Adults at Increased Risk for HIV Infection - 23 Urban Areas, United States, 2019

Amy R Baugher et al. MMWR Morb Mortal Wkly Rep. .

Abstract

In 2019, heterosexual sex accounted for 23% of new HIV diagnoses in the United States and six dependent areas (1). Although preexposure prophylaxis (PrEP) can safely reduce the risk for HIV infection among heterosexual persons, this group is underrepresented in PrEP research (2). CDC analyzed National HIV Behavioral Surveillance (NHBS) data to describe PrEP awareness among heterosexually active adults in cities with high HIV prevalence. Overall, although 32.3% of heterosexually active adults who were eligible were aware of PrEP, <1% used PrEP. Racial, ethnic, and gender disparities were identified, with the lowest awareness of PrEP among residents of Puerto Rico (5.8%) and Hispanic or Latino (Hispanic) men (19.5%) and women (17.6%). Previous studies have found that heterosexual adults are interested in taking PrEP when they are aware of it (3); tailoring PrEP messaging, including Spanish-language messaging, to heterosexual adults, might increase PrEP awareness and mitigate disparities in use.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Percentage of HIV-negative heterosexually active men and women who had heard of preexposure prophylaxis (N = 9,359), by race, ethnicity, and gender — National HIV Behavioral Surveillance, 23 urban areas, United States, 2019 Abbreviations: AI/AN = American Indian/Alaska Native; NH/OPI = Native Hawaiian/Other Pacific Islander. * Hispanic persons could be of any race; other race groups were non-Hispanic. NH/OPI, AI/AN, and Asian men and women included ≤15 persons per group.

References

    1. CDC. HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil...
    1. Bailey JL, Molino ST, Vega AD, Badowski M. A review of HIV pre-exposure prophylaxis: the female perspective. Infect Dis Ther 2017;6:363–82. 10.1007/s40121-017-0159-9 - DOI - PMC - PubMed
    1. Bradley E, Forsberg K, Betts JE, et al. Factors affecting pre-exposure prophylaxis implementation for women in the United States: a systematic review. J Womens Health (Larchmt) 2019;28:1272–85. 10.1089/jwh.2018.7353 - DOI - PubMed
    1. CDC. HIV surveillance special report: HIV infection, risk, prevention, and testing behaviors among heterosexually active adults at increased risk for HIV infection—National HIV Behavioral Surveillance, 23 U.S. cities, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil...
    1. Calabrese SK, Tekeste M, Mayer KH, et al. Considering stigma in the provision of HIV pre-exposure prophylaxis: reflections from current prescribers. AIDS Patient Care STDS 2019;33:79–88. 10.1089/apc.2018.0166 - DOI - PMC - PubMed